Research Article

Glycyrrhiza Polysaccharide Alleviates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice

Chunying Huang,¹ Xiaoqi Luo,¹ Lulu Li,¹ Nan Xue,¹ Yuanjie Dang,¹ Hongli Zhang,¹ Jingxuan Liu,¹ Jibing Li,² Cuiqin Li,¹ and Farong Li²

¹ Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry & Ministry of Education & National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xian, Shaanxi Province 710062, China
² School of Basic Medical Science, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province 611137, China

Correspondence should be addressed to Cuiqin Li; licuiqin16@snnu.edu.cn and Farong Li; lifarong530@163.com

Received 17 December 2021; Revised 6 March 2022; Accepted 25 March 2022; Published 8 April 2022

Academic Editor: Shih-Chao Lin

Copyright © 2022 Chunying Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Licorice is one of the most ubiquitous herbs in traditional Chinese medicine, with notable anti-inflammatory and antiulcerative effects as well as potent digestive disease therapeutic impacts; yet, its active components and mechanisms remain unclear. There is a lot of evidence that Glycyrrhiza polysaccharide (GPS) has antioxidants, improving intestinal flora, anti-inflammatory effects, etc. Hypothesis/Purpose. Here, we investigated the effects of GPS on dextran sulfate sodium (DSS)-induced acute ulcerative colitis (UC) mice and its possible mechanisms. Methods. GPS (100, 200, and 400mg/kg) or the positive control drug sulfasalazine (SASP) (200mg/kg) were orally administered to mice for 8 days. Body weight was recorded daily. Symptoms associated with UC, such as disease activity index (DAI), colon length, spleen weight, and mucosal damage were detected. The possible mechanism of GPS ameliorating enteritis symptoms was explored by detecting intestinal permeability and serum levels of inflammatory factors, and changes in intestinal permeability were expressed by serum concentration of FITC-dextran and D-lactic acid. Results. The results demonstrated that GPS administration alleviated UC symptoms in colitis mice, including weight loss, DAI index, shorting colon length, and mucosal damage. Mechanistic evaluation revealed that GPS treatment reduced intestinal permeability and serum levels of inflammatory factors: IL-1, IL-6, and TNF-α, while increasing serum levels of the anti-inflammatory factor IL-10, suggesting that GPS’s mechanism in UC is related to reducing intestinal permeability and inhibiting the inflammatory response, with intestinal permeability implicated as the initiating mechanism. Conclusion. This study highlights GPS as a promising therapeutic agent, with high therapeutic efficacy and a good safety profile, for enteritis and beyond.

1. Introduction

Ulcerative colitis (UC) is a recurrent chronic gastrointestinal disease that seriously endangers human health [1]. UC lesions typically are present in the colonic mucosa and submucosa; its clinical symptoms include weight loss, bloody diarrhea, a potential increase in colon cancer risk, and in severe cases death [2]. UC is predominantly characterized by increased intestinal permeability and inflammation responses, and restoring mucosal barrier function has been theorized as a possible therapeutic approach to combat this disease [3]. Numerous factors are implicated in UC pathogenesis, including the deletion and variation of a series of susceptibility genes, environmental changes, abnormalities of the intestinal microbiota, and widespread immune dysregulation; however, the specific pathogenesis of UC remains unclear [4]. Current UC therapeutics target suppressing immune reactions and reducing inflammatory factors, with the short-term treatment goal of reducing mucosal inflammation and mucosal damage [5]. Notably, these drugs have severe adverse effects such as vomiting, anemia, and generalized edema [6]. Moreover, while
minimizing mucosal inflammation and damage are admirable short-term goals, mucosal healing could provide similar immediate benefits as well as achieve longer-term treatment outcomes [7].

Licorice is widely used across Chinese medicine formulas for its anti-inflammatory, antiulcer, heat-clearing, and detoxifying effects, with it said that “9 out of 10 formulas contain licorice” [8]. According to the Chinese Pharmacopoeia, licorice refers to the roots of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat., or Glycyrrhiza glabra L. used as a medicinal material (State Pharmacopoeia Committee, China, 2020). Research has shown that licorice extracts exhibit a good therapeutic effect on ulcerative colitis [9], with numerous potential active ingredients identified: polysaccharides, saponins, and flavonoids [8].

In particular, studies have shown that components in licorice have excellent anti-inflammatory properties [10]. Glycyrrhizin has been shown to reduce levels of nitric oxide, TNF-α, and PGE2 in LPS-stimulated macrophages. Glycyrrhetic acid and glycyrrhizin have also exhibited anti-inflammatory effects via the inhibition of proinflammatory cytokines IL-6 and IL-1β, and regulation of the NF-κB pathway in LPS-treated RAW264.7 macrophages [11]. Furthermore, glycyrrhizic acid has been considered one of the major active components in the treatment of ulcerative colitis [12]. Glycyrrhiza polysaccharide (GPS) has recently been implicated as another primary active ingredient in licorice, with studies finding that GPS can regulate the immune system and gut microbial ecosystem [13]. Notably, gut microbiota imbalance is a main feature of UC, and several studies have confirmed that fecal microbiota transplantation could improve UC symptoms [14]. In a previous study, our group coincidentally found that GPS could dramatically increase tight junction protein ZO-1 expression in immunosuppressed mice intestinal tissues (Figure S1). Given that damage to the cell tight junction may cause an increase in intestinal permeability, a typical characteristic of UC, and GPS’s effect on the immune system and gut microbial ecosystem, we hypothesized that GPS might ameliorate UC symptoms.

Herein, we quantify GPS’s effect of on DSS-induced acute UC mice as well as its effects of on intestinal permeability and inflammatory factors. This experiment may deepen the understanding of traditional licorice use and illuminate licorice’s active substance for further therapeutic utilization.

2. Material and Methods

2.1. Animals. Sixty male Kunming mice, weighing 18 ± 2 g, were purchased from the Laboratory Animal Center of the Air Force Medical University of PLA (Xi’an, Shaanxi, China) with an animal production license number of SYKX (Shaanxi) 2014-001. All mice were bred in a standardized animal room, with free water and food intake, maintained indoor ventilation conditions, and normal day and night cycles. Relative humidity was maintained between 40 and 70% and room temperature between 18 and 22°C. Animals were acclimatized for 7 days. The experimental protocol was approved by the Committee on the Ethics of Animal Experiments of Shaanxi Normal University (no. ECES-2018-0223).

2.2. Glycyrrhiza Polysaccharide (GPS) Preparation. Radix Glycyrrhiza was purchased from Tianjin China Medico Technology Co., Ltd., and was identified as the root of Glycyrrhiza uralensis Fisch by professor Lijuan Zhang. The voucher specimens were kept by Tianjin China Medico Technology Co. Ltd., specimen number SSBC-G-055. 1 kg of dried Radix Glycyrrhiza was milled with a multifunctional grinder, diluted with distilled water to a 1 : 10 (w/v) ratio, and then extracted for 2 h at 90°C; this process was repeated two additional times. Subsequently, the extract was concentrated and settled overnight in 80% ethanol. The precipitate was then collected by centrifugation. After protein removal via the Sevag method, the solution was concentrated and lyophilized to obtain crude Glycyrrhiza polysaccharide (GPS). The yield of GPS was calculated by following equation:

\[ \text{Yield (w/w\%)} = M1/M2 \times 100\% \]

2.3. GPS Molecular Weight Determination. The average GPS molecular weight was determined by gel permeation chromatography: Agilent 1200 HPLC system (Agilent Technologies Co., Ltd., USA); column, Dr. Maisch GembH Reprosil 125 SEC; oven temperature, 30°C; mobile phase, deionized water; flow rate, 0.5 mL/min; ELSD detector. Molecular weight standard curves were obtained via dextran standards of differing molecular weights (1.98 × 10^2, 4.32 × 10^3, 1.26 × 10^4, 7.08 × 10^4, 1.26 × 10^5 g/mol); the molecular weight of GPS and its fractions were calculated then by the standard curve.

2.4. GPS Monosaccharide Composition. GPS was hydrolyzed in 2 mol/L trifluoroacetic acid solution, and the composition of the hydrolyzed products analyzed by HPLC after precolumn derivatized with 1-phenyl-3-methyl-5-pyrazolon (PMP) (Solarbio Life Science Co., Ltd, Beijing, China) with a quaternary pump, autosampler, degasser, and automatic thermostatic column compartment. A ZORBAXSB-C18 (4.6 mm × 150 mm, 5.0 μm) column was used. Monosaccharide standards: D-glucose (Glu), D-mannose (Man), L-rhamnose (Rha), D-glucuronic acid (GluUA), D-galactose (Gal), D-galacturonic acid (GalUA), L-arabinose (Ara), and D-xyllose (Xyl) were purchased from the National Institute for Food and Drug Control (Beijing, China).

2.5. DSS-Induced UC Mice Model and Animal Treatment. After the 7 day adaptation period, mice were randomly divided into 6 groups according to body weight. The 6 groups were the normal control group (NC), model group (Model), high-dose GPS group (GPSH, 400 mg/kg-d), medium-dose GPS group (GPSM, 200 mg/kg-d), low-dose GPS group (GPSL, 100 mg/kg-d), and positive drug group...
2.6. Evaluation of UC Progression. Disease activity index (DAI) scores, spleen index, and colon length were used to evaluate UC progression. DAI scores were based on weight loss, fecal structure, and fecal occult blood [18], and the DAI scoring criteria are shown in Table 1.

2.7. Histological Examination. Histopathological studies were performed on paraffin embedded, 5 μm thick distal colon sections, and stained with haematoxylin and eosin, followed by a blinded scoring of histologic lesions as described previously in the literature [19].

Table 1: The DAI scoring criteria.

| DAI score | Weight loss (%) | Stool consistency | Occult/gross bleeding |
|-----------|-----------------|-------------------|-----------------------|
| 0         | None            | Normal            | Normal                |
| 1         | 1–5             | Loose stools      | Hemoccult positive    |
| 2         | 5–10            |                   |                       |
| 3         | 10–20           |                   |                       |
| 4         | >20             | Diarrhea          | Gross bleeding        |

2.8. FITC-Dextran Serum Content. FITC-dextran (FD4) serum concentration was used to assess mice intestinal permeability. All mice were fasted for 4h, then intra-gastrically administered 0.2 mL FITC-dextran solution (FITC-dextran, 4 kDa, 40 mg/100 g) (Sigma-Aldrich, USA). All mice were then rested for 5 h without food or water. After anesthesia, blood was collected from orbital sinuses. The blood was then placed into 1.5 mL conical tubes and centrifuged at 3500 rpm for 10 min at 4°C. 75 μL of each serum, in triplicate, were then aliquoted into a 96-well plate. FITC-dextran fluorescence was then measured on a fluorescence plate reader via suitable wavelengths (excitation maximum 488 nm, emission maximum 525 nm) [20]. The exact FITC-dextran serum concentration was then calculated according to FITC-dextran standard curves.

2.9. D-Lactic Acid Serum Content. ELISA was used to detect serum D-lactic acid content according to the manufacturer’s instructions on the kit. A linear regression curve was used to calculate the concentration of each sample.

2.10. Cytokine Measurement. Serum levels of IL-1, IL-6, IL-10, and TNF-α were measured using ELISA (Shanghai Enzymology Laboratory Equipment Co. Ltd., Shanghai, China), according to the manufacturer’s instructions on the kit. The standard concentration was set as the abscissa, and the OD value was set as the ordinate; a standard curve was then drawn, and the concentration of corresponding cytokines was calculated.

2.11. Statistical Analysis. All results were presented as mean ± SD. Results were analyzed using GraphPad Prism version 5.0 program. One-way analysis of variance was used for comparison between groups. p < 0.05 was considered statistically significant.

3. Results

3.1. Glycyrrhiza Polysaccharide (GPS) Preparation. GPS was obtained via water extraction and alcohol precipitation, and the yield of GPS was 7.35 ± 0.12% (n = 3).

3.2. Total GPS Sugar and Protein Content. Total sugar content was assayed by the phenol-sulfate method, with glucose as the standard. Average GPS polysaccharide content was 43.50 ± 1.97% (n = 5). Total protein content was measured by the Coomassie brilliant blue method. Average GPS protein content was 4.50 ± 0.12% (n = 5).

3.3. GPS Molecular Weight. GPS’s molecular weight was determined via high-performance gel permeation chromatography. The standard molecular weight curves were based on dextran of differing molecular weights: \( y = 25.749x + 0.0572 \) (\( R^2 = 0.9949 \)). Average molecular weight of GPS was determined to be 1.26 × 10^5 Da.

3.4. GPS Monosaccharide Composition. Based on retention times, GPS’s monosaccharide composition was determined to be rhamnose, glucuronic acid, galacturonic acid, glucose, and galactose; the relative content ratio of each monosaccharide was 1.6:2.0:4.3:1:26, respectively, according to peak area.

3.5. General Mice Condition. Mice in the normal control group (NC) performed well and exhibited a normal mental status. After 6 days of DSS treatment, the mice in the model group (Model) had sluggish eyes, laid down, slumped, consumed significantly reduced water and food intake, and had loose or bloody stool. After 8 days of therapeutic administration, with GPS or SASP, the condition of the mice improved.
3.6. GPS Decreases DAI Scores of UC Mice. Animals’ DAI scores are shown in Figure 1. Compared with the NC by Wilcoxon rank-sum test, the DAI score of the Model (3.073 ± 0.362) was increased. Compared with the Model, the DAI scores of GPS (GPSH, 1.326 ± 0.119; GPSM, 1.168 ± 0.131; GPSL, 1.841 ± 0.141) and SASP groups (2.413 ± 0.268) were significantly decreased. Furthermore, the DAI score of the high-dose GPS group was significantly reduced compared with the SASP group, indicating that GPS has a superior UC relief effect and in a dose-dependent manner.

3.7. GPS Inhibits DSS-Induced Weight Loss in Mice. In the NC group, body weight increased slightly during the entire observation period. After 3 days of DSS administration, mice began to exhibit a weight loss trend (Figure 2). When treated with GPS or SASP, mice weights tended to increase from day 7 to day 15 and their mental statuses notably improved. On day 11, the GPSH’s body weights (34.21 ± 2.13) had returned to near those of the NC (35.16 ± 2.03). These results indicate that GPS can inhibit DSS-induced mice weight loss.

3.8. GPS Colon Length Effect. In UC Model mice (8.25 ± 0.54), the length of the colon was significantly shortened compared with the NC (10.38 ± 0.96). Both GPS (GPSH, 9.76 ± 0.65; GPSM, 9.69 ± 0.72; GPSL, 9.68 ± 0.93), and SASP (9.65 ± 0.38) treatments alleviated the effects of DSS on colon shortening and were significantly different from the Model (Figure 3).

3.9. GPS Effect on UC Mice Spleen Weight. Compared with the NC (0.073 ± 0.005), the spleen weight of UC Model mice (0.089 ± 0.020) were increased significantly. After GPS treatment (GPSH, 0.067 ± 0.015; GPSM, 0.072 ± 0.010; GPSL, 0.072 ± 0.019), spleen weight significantly decreased compared with the Model (Figure 4). SASP (0.078 ± 0.020) treatment also decreased spleen weight compared to the Model; however, the difference was not statistically significant. These findings suggest that GPS can ameliorate splenomegaly in UC mice.

3.10. Histological Examination. No histopathological changes were observed in the NC. In contrast, the Model mucosa exhibited mixed inflammatory infiltrates and mucosal damage (black arrows), epithelial cell shedding, and tissue hyperplasia (Figure 5(a)). Compared to the Model group, histopathological changes were significantly ameliorated in GPS and SASP groups, as demonstrated by histopathological score (Figure 5(b)).

3.11. GPS Effect on FITC-Dextran Concentration in DSS-Induced Acute UC Mice. FITC-dextran has a molecular weight of about 40 kDa; due to this high molecular weight, it does not easily diffuse into the blood via the intestinal epithelium, and so FITC-dextran serum concentration in serum can effectively serve as a fluorescent agent reflecting intestinal permeability [21]. UC is universally accompanied by an increase in intestinal inflammation and an increase in intestinal permeability [3]. Compared with the NC (180 ± 57), serum FITC-dextran content in the Model (271 ± 94) increased significantly; compared with the Model, serum FITC-dextran content was significantly decreased in the GPS and SASP (185 ± 24) groups. Notably, the serum FITC-dextran content of the GPSH (102 ± 17) was significantly decreased compared to the SASP and even significantly below that in the NC (Figure 6). These results demonstrate that GPS treatment can significantly reduce the increase in intestinal permeability in UC mouse model induced by DSS.

3.12. Effects of GPS on D-Lactic Acid (D-LAC) Concentration in DSS-Induced UC Mice. D-lactic acid is a metabolite produced by intestinal bacterial fermentation, entering...
blood circulation when intestinal permeability increases. Accordingly, serum lactic acid content can be used as an additional indicator of intestinal permeability [22].

Compared with the NC (83.41 $\pm$ 6.54), serum D-lactic acid content of the Model (96.84 $\pm$ 6.66) were significantly increased. Compared with the Model, the serum D-lactic acid content in the GPS treatment groups decreased significantly. Furthermore, the serum D-lactic acid content of the GPSH (83.17 $\pm$ 5.22) and GPSM (85.07 $\pm$ 4.09) were significantly lower than the SASP group (90.82 $\pm$ 5.89) (Figure 7). This experiment demonstrates that GPS treatment can significantly reduce the increase in intestinal permeability associated with DSS-induced UC, at both high and medium doses.

3.13. GPS Effect on Cytokine Levels in DSS-Induced UC Mice. TNF-$\alpha$, IL-1, IL-6, and IL-10 are important cytokines involved in immune responses and mediate inflammatory responses [23]. Compared with the NC, the serum levels of IL-1, IL-6, and TNF-$\alpha$ in the Model were significantly increased and the serum IL-10 levels were significantly reduced. Compared with the Model, serum levels of TNF-$\alpha$, IL-1, and IL-6 in the GPS mice groups at each dose were significantly reduced, and serum IL-10 levels significantly increased (Figure 8). These results suggest that GPS treatment can inhibit the inflammatory response in UC mice.

4. Discussion

This study demonstrates that GPS can relieve the weight loss, colon shortening, diarrhea, and stool bleeding clinical symptoms associated with DSS-induced UC mice. Furthermore, GPS inhibits the release of proinflammatory factors IL1, IL6, and TNF-$\alpha$, and promotes the production of anti-inflammatory factor IL-10, thereby inhibiting the inflammatory response. The multiple indicators observed in this study exhibit that GPS’s therapeutic effect on DSS-induced UC mice is superior to the clinical drug SASP. GPS exhibited statistically superior performance in DAI score and intestinal permeability, and nonsignificant enhancements over SASP in the other tested indicators such as spleen weight, proinflammatory factors IL1, IL6, and TNF-$\alpha$ and anti-inflammatory factor IL-10. Given its excellent safety profile of polysaccharides [24], as significant weakness in current UC therapies, this study highlights GPS’s
remarkable potential as a candidate for the treatment of irritable bowel syndrome.

Although GPS can effectively reduce intestinal permeability and intestinal inflammation, its mechanism remains unclear. One of the primary characteristics of UC is the increase in intestinal permeability [3], which allows antigens in the digestive tract enter into the body and induce inflammation; inflammation can lead to mucosal damage and aggravate UC symptoms. A reduction in intestinal permeability could inhibit the entry of macromolecular antigens into the body, subsequently reducing the inflammatory response and therefore mucosal damage. In other words, both increased inflammatory response and increased intestinal permeability are likely causes of UC, and the two are mutually causal. This study shows that GPS can reduce both intestinal permeability and the inflammatory response but...
does not elucidate which effects occur first. According to the serum FITC-dextran content, the intestinal permeability of FITC-dextran in the GPS treatment groups were even lower than that in the NC; the difference between the NC and GPSH was statistically significant, with the NC expressing no UC symptoms and normal proinflammatory factors. Therefore, we hypothesize that GPS reduces intestinal permeability prior to inducing anti-inflammatory effect and that GPS’s mechanism in alleviating DSS-induced UC may be related to its promotion of intestinal mucosal barrier function. Follow-up research will focus on possible molecular mechanisms by which GPS affects intestinal permeability.

The intestinal mucosal barrier is a crucial barrier in the body against external pathogens and toxins. If the intestinal mucosa is damaged under various pathological effects, it will cause a variety of inflammatory diseases, notably ulcerative colitis, infectious colitis, and parenteral diseases [25]. The restoring or improving the intestinal mucosal barrier plays an important role in curing these diseases and is a potential therapeutic strategy for ulcerative colitis; many drugs such as bilirubin, chitosan, and fucoidan may alleviate enteritis symptoms via enhancing intestinal barrier function.

The traditional licorice usage has shown an antiulcer effect, an effect which may be related to mucosal repair. GPS’s effect on the reduction of intestinal permeability could indicate that licorice has a mucosal repair effect. Previous studies have shown that glycyrrhizin and glycyrrhetic acid from licorice have antiulcer effects and attributed these to their anti-inflammatory effects as well as identified them as the primary active compounds [23]. This paper challenges these assertions, highlighting GPS as—at least—another active component of licorice, partially responsible for licorice’s intestinal permeability and anti-inflammatory effects.

Polysaccharides are nutrients of intestinal bacteria, which affect gut microbiota composition [26]. Changes in the gut microbiota have been linked to inflammation responses, in both positive and negative angles. Further, fecal microbiota transplantation has been shown relieve the symptoms of UC or irritable bowel disease [14]. Some studies have found that GPS has a regulatory effect on intestinal microflora, highlighting another potential mechanism of action [13]. Whether GPS’s therapeutic effect on UC...
is related to changes in gut microbiota is another question warranting further exploration.

5. Conclusion
GPS can relieve the clinical symptoms of DSS-induced UC mice as well as regulate inflammatory factors, inhibiting the inflammatory response. Highlighting an understudied active compound in millennia-old licorice medication, this study provides an experimental basis for the use of GPS in UC treatment and indicates intestinal permeability to be its primary mechanism of action.

Data Availability
The data used and analyzed during the current study are available from the first author and corresponding author on reasonable request.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions
Chunying Huang and Xiaoqi Luo contributed equally to this work.

Acknowledgments
This study was supported by the National Key R&D Program of China (2018YFC1706500) and the Fundamental Research Funds for the Central Universities (grant nos. GK201706008, 1301031898, and GK202001006).

Supplementary Materials
Figure S1: effects of GPS and DGPS on tight junction protein ZO-1 expression in immunosuppressed mice (x ± s, n = 3). ∗p < 0.05; ∗∗p < 0.01 vs. normal control; ∗∗∗p < 0.01 vs. model; **p < 0.01 vs. GPS. NC: normal group; PC: positive drug group; Model: model group; DGPS: Glycyrrhiza polysaccharide hydrohydrolytic group; GPS: Glycyrrhiza polysaccharide group. (Supplementary Materials)

References
[1] R. C. Langan, P. B. Gotsch, M. A. Krafczyk, and D. D. Skillinge, “Ulcerative colitis: diagnosis and treatment,” American Family Physician, vol. 76, no. 9, pp. 1323–1330, 2007.
[2] G. Bahrami, H. Malekshahi, S. Miraghaee et al., “Protective and therapeutic effects of aloe vera gel on ulcerative colitis induced by acetic acid in rats,” CLINICAL NUTRITION RESEARCH, vol. 9, no. 3, pp. 223–234, 2020.
[3] T. J. Keane, J. Dziki, E. Sobieski et al., “Restoring mucosal barrier function and modifying macrophage phenotype with an extracellular matrix hydrogel: potential therapy for ulcerative colitis,” Journal of Crohn’s & colitis, vol. 11, no. 3, pp. 360–368, 2017.
[4] X. N. Tang, X. Li, and Y. F. Wang, “Butyric acid increases the therapeutic effect of EHLJ7 on ulcerative colitis by inhibiting JAK2/STAT3/SOCS1 signaling pathway,” Frontiers in Pharmacology, vol. 10, 2020.
[5] M. Kayal and S. Shah, “Ulcerative colitis: current and emerging treatment strategies,” Journal of Clinical Medicine, vol. 9, no. 1, p. 94, 2019.
[6] A. I. Sanchez-Garrido, V. Prieto-Vicente, and V. Blanco-Gozalo, “Preventive effect of cardiotrophin-1 administration before DSS-induced ulcerative colitis in mice,” Journal of Clinical Medicine, vol. 8, no. 12, 2019.
[7] Y. Wang, Q. Xie, Y. Zhang et al., “Combination of probiotics with different functions alleviate DSS-induced colitis by regulating intestinal microbiota, IL-10, and barrier function,” Applied Microbiology and Biotechnology, vol. 104, no. 1, pp. 335–349, 2020.
[8] C. Wang, L. Chen, C. Xu et al., “A comprehensive review for phytochemical, pharmacological, and biosynthesis studies on Glycyrrhiza spp,” The American Journal of Chinese Medicine, vol. 48, no. 1, pp. 17–45, 2020.
[9] Y. D. Jeon, K. S. Bang, M. K. Shin, J. H. Lee, Y. N. Chang, and J. S. Jin, “Regulatory effects of glycyrrhizae radix extract on DSS-induced ulcerative colitis,” BMC Complementary and Alternative Medicine, vol. 16, p. 459, 2016.
[10] G. E. Battha, A. M. Beshbishy, A. El-Mleeh, M. M. Abdel-Daim, and H. P. Devkota, “Traditional uses, bioactive chemical constituents, and pharmacological and toxicological activities of Glycyrrhiza glabra L. (Fabaceae),” Biomolecules, vol. 10, no. 3, 2020.
[11] J.-Y. Yu, J. Ha, K.-M. Kim, Y.-S. Jung, J.-C. Jung, and S. Oh, “Anti-inflammatory activities of licorice extract and its active compounds, glycyrrhizic acid, liquiritin and liquiritigenin, in BV2 cells and mice liver,” Molecules, vol. 20, no. 7, pp. 13041–13054, 2015.
[12] Y. D. Jeon, S. H. Kang, K. S. Bang, Y. N. Chang, J. H. Lee, and J. S. Jin, “Glycyrrhetic acid ameliorates dextran sulfate sodium-induced ulcerative colitis in vivo,” Molecules (Basel, Switzerland), vol. 21, no. 4, p. 523, 2016.
[13] X. Zhang, S. Zhao, X. Song et al., “Inhibition effect of glycyrrhiza polysaccharide (GCP) on tumor growth through regulation of the gut microbiota composition,” Journal of Pharmacological Sciences, vol. 137, no. 4, pp. 324–332, 2018.
[14] Y. He, X. Li, H. Yu et al., “The functional role of fecal microbiota transplantation on dextran sulfate sodium-induced colitis in mice,” Frontiers in Cellular and Infection Microbiology, vol. 9, p. 393, 2019.
[15] Y. T. Liang, J. H. Zhou, and T. G. Nan, “Analysis of monosaccharide composition of twelve polysaccharides by pre-column derivatization procedure UPLC-MS/MS,” Zhongguo Zhongyao Zazhi, vol. 43, no. 22, pp. 4469–4473, 2018.
[16] Y. D. Qin, R. B. Wang, and J. J. Zhou, “Analysis of monosaccharide compositions in paeoniae radix alba polysaccharide,” Zhong Yao Cai, vol. 38, no. 11, pp. 2335–2338, 2015.
[17] K. Zhou, R. Cheng, B. Liu, L. Wang, H. Xie, and C. Zhang, “Eupatilin ameliorates dextran sulphate sodium-induced colitis in mice partly through promoting AMPK activation,” Phytotherapy, vol. 46, pp. 46–56, 2018.
[18] H. Chen, H. Shi, Y. Liu et al., “Activation of corticotropin-releasing factor 1 aggravates dextran sodium sulphate-induced colitis in mice by promoting M1 macrophage...
polarization,” Molecular Medicine Reports, vol. 17, no. 1, pp. 234–242, 2018.

[19] S. N. Murthy, H. S. Cooper, H. Shim, R. S. Shah, S. A. Ibrahim, and D. J. Sedergran, “Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin,” Digestive Diseases and Sciences, vol. 38, no. 9, pp. 1722–34, 1993.

[20] J. M. Monk, W. Wu, D. Lepp et al., “Navy bean supplemented high-fat diet improves intestinal health, epithelial barrier integrity and critical aspects of the obese inflammatory phenotype,” The Journal of Nutritional Biochemistry, vol. 70, pp. 91–104, 2019.

[21] L. Hartmann, X. Zhao, T. Macheroux, M. S. Kasparek, M. E. Kreis, and M. H. Mueller, “Time-dependent alterations of gut wall integrity in small bowel obstruction in mice,” Journal of Surgical Research, vol. 233, pp. 249–255, 2019.

[22] C.-Y. Zhan, D. Chen, J.-L. Luo, Y.-H. Shi, and Y.-P. Zhang, “Protective role of down-regulated microRNA-31 on intestinal barrier dysfunction through inhibition of NF-κB/HIF-1α pathway by binding to HMOX1 in rats with sepsis,” Molecular Medicine, vol. 24, no. 1, p. 55, 2018.

[23] J.-X. Zhou and M. Wink, “Evidence for anti-inflammatory activity of isoliquiritigenin, 18β glycyrrhetinic acid, ursolic acid, and the traditional Chinese medicine plants Glycyrrhiza glabra and eriobotrya japonica, at the molecular level,” Medicines, vol. 6, no. 2, p. 55, 2019.

[24] W. Niu, X. Q. Chen, and R. L. Xu, “Polysaccharides from natural resources exhibit great potential in the treatment of ulcerative colitis: a review,” Carbohydrate Polymers, vol. 254, 2021.

[25] F. Sánchez de Medina, I. Romero-Calvo, C. Mascaraque, and O. Martínez-Augustin, “Intestinal inflammation and mucosal barrier function,” Inflammatory Bowel Diseases, vol. 20, no. 12, pp. 2394–2404, 2014.

[26] N. M. Koropatkin, E. A. Cameron, and E. C. Martens, “How glycan metabolism shapes the human gut microbiota,” Nature Reviews Microbiology, vol. 10, no. 5, pp. 323–335, 2012.